ImmunoPrecise Antibodies
- Country
- 🇨🇦Canada
- Ownership
- Public
- Established
- 1983-01-01
- Employees
- 101
- Market Cap
- $20.9M
- Introduction
ImmunoPrecise Antibodies Ltd. is a therapeutic antibody discovery company, which engages in the provision of human therapeutic antibody discovery and development services. The firm offers a selection of antibodies, enzymes, enzymes activity assays, arthritis animal products, proteins, deiminated proteins, and hybridoma licensing for research purposes. The company was founded by Robert Beecroft on November 22, 1983 and is headquartered in Victoria, Canada.
ImmunoPrecise's AI-Designed GLP-1 Peptides Outperform Semaglutide in Receptor Activation Studies
ImmunoPrecise Antibodies announced that its AI-designed GLP-1 receptor agonist peptides achieved comparable or superior receptor activation to Semaglutide in independent third-party in vitro studies.
India Launches ₹5,000 Crore Pharma R&D Fund to Boost Innovation and Reduce Import Dependence
India has introduced a ₹5,000 crore research and development fund under the Promotion of Research & Innovation in Pharma MedTech Sector (PRIP) scheme to strengthen capabilities in drug discovery, medical technology, and stem cell therapy.
ImmunoPrecise Antibodies Secures $10M Partnership for AI-Driven Cancer Therapeutics Development
ImmunoPrecise Antibodies has formed a strategic $8-10M partnership with a leading biotechnology company to develop novel cancer therapeutics using AI-driven discovery platforms.
ImmunoPrecise and RIBOPRO Form Strategic Alliance to Advance mRNA-Driven Antibody Discovery
ImmunoPrecise Antibodies Ltd. and RIBOPRO have established a strategic partnership combining AI-powered antibody discovery with advanced mRNA and lipid nanoparticle technologies.